Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Journey Medical Corp (DERM)

Journey Medical Q1 revenue rises 21% to $16.0 million; net loss narrows

Positive Impact 3 of 5 earnings Written later

Journey Medical reported first-quarter 2026 results for the three months ended March 31, 2026. Total revenue rose 21% to $16.0 million and the net loss narrowed to $2.2 million, or $(0.08) per share, from $4.1 million, or $(0.18) per share, a year earlier. Gross margin fell to 61.0% because of a $1.3 million non-cash inventory write-down tied to a 2021 Qbrexza asset acquisition.

Key points

  • Total revenue was $16.0 million, up from $13.1 million in the first quarter of 2025.
  • Emrosi revenue was $6.3 million, compared with $2.1 million a year earlier.
  • Gross margin decreased to 61.0% from 63.5%, mainly due to a $1.3 million non-recurring non-cash charge.
  • Cash and cash equivalents were $27.2 million at March 31, 2026, up from $24.1 million at December 31, 2025.

The filing

CompanyJourney Medical Corp (DERM)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:06 PM ET
Accession number0001104659-26-060232

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.